Correction

In the article by P. F. Bross, et al., which appeared in the June 2001, issue of Clinical Cancer Research (pp. 1490–1496), the currently approved labeled indication is for patients “sixty years of age or older who are not candidates for other cytotoxic chemotherapy.” The original label was revised to clarify that Gemtuzumab ozogamicin is in itself highly cytotoxic. The intent was to limit the use of this product to patients who might otherwise not be able to receive treatment for their relapsed leukemia, until further studies can be completed confirming clinical benefit in other clinical situations.

Due to manufacturing constraints, approximately 50% of the antibody is unconjugated. The average molar loading ratio is 2–3 molecules of calechiamicin/antibody, not 4–6 molecules/antibody as reported in the article. However of the conjugated molecules, the molar loading is closer to 4–6 molecules/antibody. The clinical effect of the unconjugated antibodies is unknown.

The infusion time is two hours, not four hours as reported in the article. In the abstract, the correct units to report platelet count are 30,000/μl not 30,000 per ml. On page 1492, “Pharmacokinetics,” the corrected units for AUC are mg-hr/liter. On page 1493, first column, 61 was the median age, not the mean age.

In the article by Wen G. Jiang et al., which appeared in the August 2001, issue of Clinical Cancer Research (pp. 2555–2562), the name of author Roger Abounder was misspelled. The correct spelling is Roger Abounader.